Geertrui Denecker
Overview
Explore the profile of Geertrui Denecker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Decaesteker B, Louwagie A, Loontiens S, De Vloed F, Bekaert S, Roels J, et al.
Nat Commun
. 2023 Mar;
14(1):1267.
PMID: 36882421
The pediatric extra-cranial tumor neuroblastoma displays a low mutational burden while recurrent copy number alterations are present in most high-risk cases. Here, we identify SOX11 as a dependency transcription factor...
2.
Afanasyeva E, Gartlgruber M, Ryl T, Decaesteker B, Denecker G, Monke G, et al.
Life Sci Alliance
. 2021 Mar;
4(5).
PMID: 33658318
The migrational propensity of neuroblastoma is affected by cell identity, but the mechanisms behind the divergence remain unknown. Using RNAi and time-lapse imaging, we show that ADRN-type NB cells exhibit...
3.
Mus L, Van Haver S, Popovic M, Trypsteen W, Lefever S, Zeltner N, et al.
Genes Chromosomes Cancer
. 2020 Dec;
60(4):272-281.
PMID: 33336840
Human embryonic stem cells (hESCs) and embryonal tumors share a number of common features, including a compromised G1/S checkpoint. Consequently, these rapidly dividing hESCs and cancer cells undergo elevated levels...
4.
Vandamme N, Denecker G, Bruneel K, Blancke G, Akay O, Taminau J, et al.
Cancer Res
. 2020 Jun;
80(14):2983-2995.
PMID: 32503808
Epithelial-to-mesenchymal transition (EMT)-inducing transcription factors (TF) are well known for their ability to induce mesenchymal states associated with increased migratory and invasive properties. Unexpectedly, nuclear expression of the EMT-TF ZEB2...
5.
Mus L, Lambertz I, Claeys S, Kumps C, Van Loocke W, Van Neste C, et al.
Sci Rep
. 2020 Jan;
10(1):218.
PMID: 31937834
Neuroblastoma is an aggressive childhood cancer arising from sympatho-adrenergic neuronal progenitors. The low survival rates for high-risk disease point to an urgent need for novel targeted therapeutic approaches. Detailed molecular...
6.
Rombaut D, Chiu H, Decaesteker B, Everaert C, Yigit N, Peltier A, et al.
Sci Rep
. 2019 Jul;
9(1):10536.
PMID: 31311990
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
7.
Vanhauwaert S, Decaesteker B, De Brouwer S, Leonelli C, Durinck K, Mestdagh P, et al.
Sci Rep
. 2019 Jun;
9(1):8360.
PMID: 31164657
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
8.
Rombaut D, Chiu H, Decaesteker B, Everaert C, Yigit N, Peltier A, et al.
Sci Rep
. 2019 Apr;
9(1):5685.
PMID: 30952905
Long intergenic non-coding RNAs (lincRNAs) are emerging as integral components of signaling pathways in various cancer types. In neuroblastoma, only a handful of lincRNAs are known as upstream regulators or...
9.
Claeys S, Denecker G, Durinck K, Decaesteker B, Mus L, Loontiens S, et al.
Oncogene
. 2018 Dec;
38(15):2690-2705.
PMID: 30538293
ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very...
10.
Vanhauwaert S, Decaesteker B, De Brouwer S, Leonelli C, Durinck K, Mestdagh P, et al.
Sci Rep
. 2018 Dec;
8(1):17468.
PMID: 30504901
Chemotherapy resistance is responsible for high mortality rates in neuroblastoma. MYCN, an oncogenic driver in neuroblastoma, controls pluripotency genes including LIN28B. We hypothesized that enhanced embryonic stem cell (ESC) gene...